Literature DB >> 24696708

Visceral pathology of acute systemic injury in newborn mice on the onset of Coxsackie virus infection.

Lulu Wang1, Changyuan Dong1, Dong-E Chen2, Zhen Song1.   

Abstract

Coxsackievirus B (CVB) is a significant pathogen of neonatal diseases with severe systemic involvement and high mortality. Hence, it is essential to develop a CVB-induced acute systemic disease model on newborn mouse and study the injury at the onset phase. In this work, a clinical strain of CVB3, Nancy, and its variant strain, Macocy, were adopted in 24 hour old neonates by oral infection. The pathological changes in the heart, liver and lung tissues were analyzed by pathology assays. In situ end labeling assay for programmed cell death was carried out for liver tissues. The data on fatality and infection rates and pathology scores were analyzed statistically. The genomic sequences of the two strains were aligned. The model represented the manifest clinical syndromes of hepatitis, pneumonia and myocardial injury at the onset phase, in which massive numbers of hepatocytes had undergone programmed cell death. Statistical and pathological analysis indicated that the myocardial injury was mild, whereas the liver and lung were more severe. The fatality rate, infection and pathology of the two CVB strains were the same. Therefore, two nucleotide mutations in the 5' UTR and four amino acid mutations in polyprotein, which did not alter virulence, were shown. By peroral CVB infection of neonatal mice, we developed an acute systemic disease model for studying visceral pathology and systemic disease. At the onset of acute neonatal systemic disease, the hepatitis and pneumonia may be the dominant reason of death, as the injury of liver and lung is more severe than that of heart.

Entities:  

Keywords:  Coxsackievirus B; acute neonatal systemic disease; mutation sites; pathological diversity

Mesh:

Substances:

Year:  2014        PMID: 24696708      PMCID: PMC3971291     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  44 in total

1.  Clinical features of acute coxsackie B viral myocarditis.

Authors:  H Toshima; Y Ohkita; M Shingu
Journal:  Jpn Circ J       Date:  1979-05

2.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

3.  Coxsackie B virus infection of mice: inoculation by the oral route protects the pancreas from damage, but not from infection.

Authors:  Shubhada Bopegamage; Jana Kovacova; Agnesa Vargova; Jana Motusova; Anna Petrovicova; Maria Benkovicova; Pavol Gomolcak; Judith Bakkers; Frank van Kuppeveld; Willem J G Melchers; Jochem M Galama
Journal:  J Gen Virol       Date:  2005-12       Impact factor: 3.891

Review 4.  The group B coxsackieviruses and myocarditis.

Authors:  K S Kim; G Hufnagel; N M Chapman; S Tracy
Journal:  Rev Med Virol       Date:  2001 Nov-Dec       Impact factor: 6.989

5.  Epidemiological survey of neonatal non-polio enterovirus infection in the Netherlands.

Authors:  M A Verboon-Maciolek; T G Krediet; A M van Loon; J Kaan; J M D Galama; L J Gerards; A Fleer
Journal:  J Med Virol       Date:  2002-02       Impact factor: 2.327

6.  Probable intrafamilial transmission of coxsackievirus b3 with vertical transmission, severe early-onset neonatal hepatitis, and prolonged viral RNA shedding.

Authors:  Ling Ling Cheng; Pak Cheung Ng; Paul Kay-Sheung Chan; Hiu Lei Wong; Frankie Wai Tsoi Cheng; Julian Wei-Tze Tang
Journal:  Pediatrics       Date:  2006-08-14       Impact factor: 7.124

Review 7.  Bronchiolitis.

Authors:  Rosalind L Smyth; Peter J M Openshaw
Journal:  Lancet       Date:  2006-07-22       Impact factor: 79.321

8.  Viral persistence and chronic immunopathology in the adult central nervous system following Coxsackievirus infection during the neonatal period.

Authors:  Ralph Feuer; Chelsea M Ruller; Naili An; Jenna M Tabor-Godwin; Ross E Rhoades; Sonia Maciejewski; Robb R Pagarigan; Christopher T Cornell; Stephen J Crocker; William B Kiosses; Ngan Pham-Mitchell; Iain L Campbell; J Lindsay Whitton
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

9.  Profile of enterovirus disease in the first two weeks of life.

Authors:  M J Abzug; M J Levin; H A Rotbart
Journal:  Pediatr Infect Dis J       Date:  1993-10       Impact factor: 2.129

10.  Myocarditis and fulminant hepatic failure from coxsackievirus B infection.

Authors:  R B Read; R J Ede; P Morgan-Capner; G Moscoso; B Portmann; R Williams
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

View more
  3 in total

1.  MicroRNA-20b suppresses the expression of ZFP-148 in viral myocarditis.

Authors:  Hong-Fei Xu; Xiang-Ting Gao; Jun-Yi Lin; Xue-Hua Xu; Jun Hu; Yu-Jie Ding; Shao-Hua Zhu
Journal:  Mol Cell Biochem       Date:  2017-02-28       Impact factor: 3.396

2.  Human Gut-On-A-Chip Supports Polarized Infection of Coxsackie B1 Virus In Vitro.

Authors:  Remi Villenave; Samantha Q Wales; Tiama Hamkins-Indik; Efstathia Papafragkou; James C Weaver; Thomas C Ferrante; Anthony Bahinski; Christopher A Elkins; Michael Kulka; Donald E Ingber
Journal:  PLoS One       Date:  2017-02-01       Impact factor: 3.240

3.  Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination.

Authors:  Virginia M Stone; Renata Utorova; Marta Butrym; Amir-Babak Sioofy-Khojine; Minna M Hankaniemi; Emma E Ringqvist; Marfa Blanter; Anirudra Parajuli; Terezia Pincikova; Björn Fischler; Ferenc Karpati; Vesa P Hytönen; Heikki Hyöty; Lena Hjelte; Malin Flodström-Tullberg
Journal:  iScience       Date:  2022-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.